Sofwave Medical Reports Third Quarter 2026 Financial Results and Business Highlights
Key Highlights
- ➤Q3 revenue $28.5M, up 35% year-over-year
- ➤Q3 usage fee revenue $13.3M, up 60% year-over-year
- ➤Q3 IFRS net income $4.1M versus $1.0M prior year
- ➤China NMPA approved Sofwave System marketing for mainland China
- ➤Initial China order 70 systems; 10 shipped, 60 scheduled in Q4
Expert Statements
Louis Scafuri, CEO of Sofwave Medical
“Sofwave delivered another quarter of profitable growth, with revenue increasing 35% to $28.5 million and recurring usage fee revenue growing 60% to $13.3 million.”
Louis Scafuri, CEO of Sofwave Medical
“Usage fees represented 47% of total revenue, reflecting growth in treatment activity across our expanding provider network.”
Louis Scafuri, CEO of Sofwave Medical
“IFRS gross margin expanded to 76.6% from 73.7% a year ago, and IFRS operating income nearly tripled to $4.4 million.”
Louis Scafuri, CEO of Sofwave Medical
“Non-IFRS operating income increased 161% to $4.9 million, or 17.2% of revenue.”
Louis Scafuri, CEO of Sofwave Medical
“We achieved our sixth consecutive quarter of positive IFRS net income and generated $2.6 million in cash during the quarter.”
Louis Scafuri, CEO of Sofwave Medical
“The NMPA approval adds an important growth opportunity in China.”
Louis Scafuri, CEO of Sofwave Medical
“Through the first nine months, revenue grew 41% to $82.9 million.”
Shimon Eckhouse, Chairman of the Board of Sofwave Medical
“Sofwave continues to execute its business and product development plan and our third quarter financial results clearly demonstrate its successful implementation.”
Shimon Eckhouse, Chairman of the Board of Sofwave Medical
“China is one of the fastest growing global territories in medical aesthetics, and its size and vast middle class, which is highly oriented towards non-invasive aesthetic treatments, creates a great growth opportunity for Sofwave.”
* Third quarter revenue of $28.5M, +35% year-over-year growth; IFRS gross margin of 76.6% * Third quarter usage fee revenue of $13.3M, +60% year-over-year growth * First nine months revenue of $82.9M, +41% year-over-year growth; IFRS gross margin of 76.1% * Third quarter IFRS and non-IFRS net income of $4.1M and $4.6M, respectively, versus IFRS and non-IFRS net income of $1.0M and $1.4M, respectively, in the prior year period * Generated $2.6M in cash in the third quarter * Received approval in the third quarter from China’s National Medical Products Administration (NMPA) to market the Sofwave™ System in mainland China * Approximately 3,400 Sofwave systems sold to date and approximately 1.1 million Sofwave treatments administered since commercialization SAN CLEMENTE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd. (TASE: SOFW), an emerging leader in energy-based, non-invasive aesthetic medical devices for practitioners worldwide, today reported financial results for the third quarter and first nine months of fiscal year 2026, for the period ended September 30, 2026, and recent business highlights.
Get started
Create a free account to read the full story.